LONDON--(BUSINESS WIRE)--Jul 23, 2018--Technavio has announced their latest pipeline analysis report on the . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat mycosis fungoides.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180723005555/en/
Technavio has published a new report on the drug development pipeline for mycosis fungoides, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report by presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
Mycosis fungoides: Market overview
Mycosis fungoides is the most common type of cutaneous T-cell lymphoma constituting over 70% of CTCL. It mostly affects the skin and progresses internally over time. The disease progresses through various stages but not all patients with mycosis fungoides go through all stages. The final stage of mycosis fungoides is known as Sezary syndrome. If left untreated, mycosis fungoides may spread to other parts of the body such as gastrointestinal system, liver, spleen, or brain. The most common age group affected by mycosis fungoides is 40 years and above. The pattern of inheritance of mycosis fungoides is not determined. Though there have been various cases where multiple members of a family were affected with mycosis fungoides, it most often occurs in people with no history of the disorder in the family.
According to a senior market research analyst at Technavio, “On the gender front, mycosis fungoides is more common in men than in women. According to the National Institutes of Health, the prevalence of mycosis fungoides in men and women is in the ratio 2:1. The prevalence of mycosis fungoides in the US is about 3.6 people per every 1,000,000 people. As a result, with rising incidences of the disease, the need for drug development for mycosis fungoides is expected to increase considerably in the forthcoming years.”
Mycosis fungoides: Segmentation analysis
This pipeline analysis report segments the mycosis fungoides market based on therapies employed (monotherapy, combination therapy and monotherapy+combination therapy), RoA (intravenous, topical, subcutaneous, oral, intravenous + oral, parenteral, and intratumoral), therapeutic modality (small molecule, monoclonal antibody, recombinant antibody, RNA and fusion protein), targets (PD1, HDAC6, and others), MoA (PD1 inhibitor, and others), geographical segmentation (Americas, EMEA and APAC) and recruitment status (active, not recruiting, completed, not yet recruiting, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on therapeutic modality, around 44% of the molecules that are being investigated for the treatment of mycosis fungoides are small molecule.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age
Key CompaniesType of players Company overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180723005555/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL RESEARCH SCIENCE
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 07/23/2018 12:27 PM/DISC: 07/23/2018 12:28 PM